Related Experiment Video

Updated: Jun 11, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic

Jiao Mu1, Bing Feng, Zilin Ye

  • 1Institute of Nephrology of Chongqing and Department of Nephrology, Xinqiao Hospital, The Third Military Medical University, Chongqing, PR China.

Journal of Nephrology
|July 6, 2010
PubMed

Insights

Higher visfatin levels are linked to atherosclerosis in chronic kidney disease (CKD) patients. This indicates visfatin may contribute to the progression of atherosclerosis in CKD.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Chronic kidney disease (CKD) is associated with increased cardiovascular risk.
  • Atherosclerosis is a major complication in CKD patients.
  • The role of visfatin in CKD-related atherosclerosis requires further investigation.

Purpose of the Study:

  • To investigate the association between visfatin and atherosclerosis in patients with CKD.
  • To determine if visfatin levels correlate with markers of endothelial dysfunction and inflammation in CKD.

Main Methods:

  • Serum visfatin, lipid profiles, and inflammatory markers (hsCRP) were measured in 117 CKD patients (stage 4-5) and 50 controls.
  • Endothelial function was assessed using flow-mediated dilatation (FMD).
  • Carotid intima-media thickness (IMT) was measured by vascular ultrasound.

Main Results:

  • CKD patients exhibited endothelial dysfunction compared to controls.
  • Visfatin levels correlated positively with hsCRP, triglycerides, and LDL cholesterol.
  • Visfatin levels correlated negatively with HDL cholesterol, eGFR, and FMD, and positively with carotid IMT.

Conclusions:

  • Elevated visfatin levels in CKD patients are associated with impaired endothelial function, dyslipidemia, and reduced kidney function.
  • Visfatin correlates with markers of inflammation and atherosclerosis progression (IMT).
  • Visfatin may play a significant role in the development of atherosclerosis in CKD.
Abstract

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...